Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay

MT Newswires Live

04/01

Arovella Therapeutics (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer

cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.

The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.

The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.

The company's shares rose nearly 3% in recent trading on Wednesday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2624636785"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624636785\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624636785?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 10:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624636785","market":"nz","top_or_hot":-1,"title":"Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ALA.AU\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer</p><p>cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.</p><p>The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.</p><p>The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.</p><p>The company's shares rose nearly 3% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArovella Therapeutics Confirms Functionality of Claudin 18.2-Targeting CAR Against Pancreatic, Gastric Cancer in In-Vitro Assay\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-01 10:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ALA.AU\">Arovella Therapeutics</a> (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancer</p><p>cells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.</p><p>The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.</p><p>The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.</p><p>The company's shares rose nearly 3% in recent trading on Wednesday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7503","symbol_name":"科技股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2624636785","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624636785","pubTimestamp":1775011349,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Arovella Therapeutics  confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor , which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancercells when incorporated into invariant natural killer T  cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.The company's shares rose nearly 3% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7503":"科技股","BK4539":"次新股","BK7096":"制药","BK4230":"旅客陆运","BK4022":"陆运","ALA.AU":"AROVELLA THERAPEUTICS LTD","LENZ":"Therapeutics","BK4139":"生物科技","BK4007":"制药","CAR":"安飞士","CAR.AU":"CAR GROUP LTD","BK7002":"互动媒体与服务"},"translate_title":"Arovella Therapeutics在体外试验中证实了靶向Claudin 18.2的CAR抗胰腺癌、胃癌的功能","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALA.AU":1,"CAR.AU":1,"CAR":1.5,"LENZ":1.5},"content_text":"Arovella Therapeutics (ASX:ALA) confirmed the functionality of its Claudin 18.2-targeting chimeric antigen receptor (CAR), which induces effective killing of CLDN18.2-positive pancreatic cancer and gastric cancercells when incorporated into invariant natural killer T (iNKT) cells in an in-vitro serial tumor challenge assay, according to a Wednesday Australian bourse filing.The study was designed to confirm the potency of the therapy against pancreatic and gastric cancer cells, the durability of cell killing after multiple challenges of cancer cells, and the expansion and effect of the inclusion of armoring, the filing said.The inclusion of IL-12-TM armoring technology enhances the CLDN18.2 CAR-iNKT cell killing and resulted in better tumor control during repeated tumor challenges, killing over 97% and 82% of the pancreatic and gastric tumor cells, respectively, in four successive rounds, per the filing.The company's shares rose nearly 3% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}